Erythrocyte oxidative stress in clinical management of diabetes and its cardiovascular complications
Article
Article Title | Erythrocyte oxidative stress in clinical management of diabetes and its cardiovascular complications |
---|---|
ERA Journal ID | 44817 |
Article Category | Article |
Authors | Nwose, E. U., Jelinek, H. F., Richards, R. S. and Kerr, P. G. |
Journal Title | British Journal of Biomedical Science |
Journal Citation | 64 (1), pp. 35-43 |
Number of Pages | 9 |
Year | 2007 |
Publisher | Taylor & Francis |
Place of Publication | Switzerland |
ISSN | 0967-4845 |
Digital Object Identifier (DOI) | https://doi.org/10.1080/09674845.2007.11732754 |
Web Address (URL) | https://www.tandfonline.com/doi/abs/10.1080/09674845.2007.11732754 |
Abstract | Diabetes mellitus is a chronic disease in its own right and is also regarded as a cardiovascular risk factor as well as a cardiovascular disease, due to its ability to progress to a stage of cardiovascular co-morbidity. The pathophysiology of cardiovascular complications in diabetes is reported to involve hyperglycaemia-induced oxidative stress. The erythrocyte has an array of endogenous antioxidants involved in quenching oxidant production and the exponential chain reactions in diabetes. When the erythrocyte is oxidatively stressed, as demonstrated by depleted reduced glutathione and/or increased malondialdehyde in its cell membrane, the risk of diabetes progression and its cardiovascular sequelae, including atherosclerosis and coronary artery disease, is increased. Virtually all studies that determined erythrocyte malondialdehyde and glutathione in diabetes show consistently increased and reduced levels, respectively. Furthermore, cardiovascular complications of diabetes are reported to commence at the prediabetes stage. Current coronary artery disease screening programmes based on the presence of two or more risk factors are failing to identify those with increased risk of diabetes and cardiovascular complications, thereby limiting early interventions. Screening that includes erythrocyte oxidative stress determination may provide an additional marker for both preclinical and advanced disease. In this review, a concise description of the involvement of erythrocyte oxidative stress in diabetes mellitus and its cardiovascular sequelae is presented. Antioxidant action and interaction in the erythrocyte are also described, with emphasis on why current coronary artery disease screening markers cannot be regarded as erythrocyte oxidative stress markers. |
Keywords | Cardiovascular diseases; Diabetes complications; Diabetes mellitus; Erythrocytes; Oxidative stress |
Contains Sensitive Content | Does not contain sensitive content |
ANZSRC Field of Research 2020 | 420605. Preventative health care |
Public Notes | Files associated with this item cannot be displayed due to copyright restrictions. |
Byline Affiliations | Charles Sturt University |
https://research.usq.edu.au/item/z1yv3/erythrocyte-oxidative-stress-in-clinical-management-of-diabetes-and-its-cardiovascular-complications
24
total views0
total downloads0
views this month0
downloads this month